3/13
07:31 am
cue
Cue Biopharma, Inc. (NASDAQ: CUE) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $6.00 price target on the stock.
High
Report
Cue Biopharma, Inc. (NASDAQ: CUE) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $6.00 price target on the stock.
2/29
10:12 am
cue
Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium [Yahoo! Finance]
Low
Report
Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium [Yahoo! Finance]
2/29
10:00 am
cue
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
Low
Report
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
2/6
08:13 am
cue
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
High
Report
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/6
08:00 am
cue
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Medium
Report
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
1/17
08:36 am
cue
Cue Biopharma (NASDAQ:CUE) investors are sitting on a loss of 80% if they invested three years ago [Yahoo! Finance]
Medium
Report
Cue Biopharma (NASDAQ:CUE) investors are sitting on a loss of 80% if they invested three years ago [Yahoo! Finance]